(Corrects day in last paragraph to Tuesday from Monday)
* Q4 loss/shr $0.14 vs est loss/shr $0.17
* Cash and equivalents as of Dec 31 at $52.4 mln
Feb 17 Biotechnology firm Dyax Corp DYAX.O
reported a narrower-than-expected quarterly loss, helped by a
46 percent fall in research and development expenses, and said
it has sufficient cash to support ongoing operations into 2011.
For the fourth quarter, Dyax reported a net loss of $10.9
million, or 14 cents per share, compared with net income of
$6.4 million, or 10 cents per share, in the year-ago period.
Revenue was $6.3 million.
Research and development costs fell to $8.8 million from
Analysts on average were expecting the company to post a
loss of 17 cents a share, on revenue of $4.7 million for the
quarter, according to Thomson Reuters I/B/E/S.
Shares of Dyax closed at $3.34 Tuesday on Nasdaq.
(Reporting by Jennifer Robin Raj in Bangalore; Editing by Vinu